ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc (LXRX)

1.85
0.11
(6.32%)
Closed June 22 4:00PM
1.86
0.01
(0.54%)
After Hours: 7:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
1.86
Bid
1.84
Ask
1.86
Volume
6,896,627
1.73 Day's Range 1.895
0.92 52 Week Range 3.73
Market Cap
Previous Close
1.74
Open
1.78
Last Trade
1
@
1.86
Last Trade Time
Financial Volume
$ 12,463,779
VWAP
1.8072
Average Volume (3m)
2,591,041
Shares Outstanding
246,236,753
Dividend Yield
-
PE Ratio
-2.57
Earnings Per Share (EPS)
-0.72
Revenue
1.2M
Net Profit
-177.12M

About Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for ... Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Lexicon Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LXRX. The last closing price for Lexicon Pharmaceuticals was $1.74. Over the last year, Lexicon Pharmaceuticals shares have traded in a share price range of $ 0.92 to $ 3.73.

Lexicon Pharmaceuticals currently has 246,236,753 shares outstanding. The market capitalization of Lexicon Pharmaceuticals is $455.54 million. Lexicon Pharmaceuticals has a price to earnings ratio (PE ratio) of -2.57.

Lexicon Pharmaceuticals (LXRX) Options Flow Summary

Overall Flow

Bullish

Net Premium

125k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

LXRX Latest News

Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes

Lexicon Seeks Approval for Sotagliflozin as an Adjunct to Insulin Therapy for Glycemic Control in People with Type 1 Diabetes and Chronic Kidney Disease Company Anticipates Six Month Review and...

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people with diabetic peripheral neuropathic pain (DPNP...

Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness...

Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association

THE WOODLANDS, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that three poster presentations will be delivered during the 84th Scientific...

Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies Global Healthcare Conference. Jeff Wade...

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.031.63934426231.832.031.6926694581.74608939CS
40.1911.3772455091.672.031.5922565431.78571899CS
12-0.59-24.08163265312.452.451.4825910411.77890261CS
260.647.6190476191.263.731.2237149482.14025808CS
52-0.57-23.45679012352.433.730.9229039501.88970008CS
156-2.82-60.25641025644.686.32990.9216043222.37682317CS
260-4.1-68.79194630875.969.650.9219763973.15540916CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

LXRX Discussion

View Posts
jdheart101 jdheart101 1 month ago
Garbage
👍️0
dcaf7 dcaf7 2 months ago
Interesting sales estimates for Sota.
Apr 30, 2024
Leerink initiated coverage of Lexicon with an Outperform rating and $5 price target. The firm believes Lexicon’s first-in-class dual SGLT1/2 inhibitor sotagliflozin could address unmet need across multiple indications with large market opportunities, including heart failure, hypertrophic cardiomyopathy and Type 1 diabetes with chronic kidney disease, which could collectively drive blockbuster sales. Inpefa’s U.S. launch in HF should benefit from several meaningful tailwinds, Leerink says. It forecasts peak U.S. sales of $1B for Inpefa in HF and peak U.S. sales of $325M for sotagliflozin in HCM in FY32. The firm also points out that Lexicon plans to resubmit Zynquista’s NDA filing by mid-2024, with an anticipated 6-month review. Leerink forecasts peak U.S. sales of $225M for Zynquista in T1D with CKD in FY32.
👍️0
BooDog BooDog 2 months ago
Almost added back in but want to see confirmation for bottom. Double bottoms can be tricky. But even so, long term I like this.
👍️0
BooDog BooDog 2 months ago
Zacks analysis.
https://www.zacks.com/stock/news/2256264/all-you-need-to-know-about-lexicon-lxrx-rating-upgrade-to-buy

Upgrading to buy while I'm watching for the gap to fill which may put this around 1.40's. We'll see. I think analysts are always late to the party but this report is actually pretty timely.
👍️0
BooDog BooDog 3 months ago
Quite the gap there if that's what you're looking at.
👍️0
glenn1919 glenn1919 3 months ago
LXRX.......................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
dcaf7 dcaf7 3 months ago
Lexicon will resubmit an NDA for sotagliflozin for patients with type 1 diabetes and chronic kidney disease. Good news. FDA rejected an NDA for type 1 diabetes in 2019. Now they changed their mind but only for patients with T1D+CKD. According to today's company presentation, slide 10, this population makes 21% of adults with T1D, or ~357,000 patients. Not a big addition to current indication. However, it will be the first gliflozin approved for T1D. No competition.
👍️ 1
Awl416 Awl416 3 months ago
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
👍️0
BooDog BooDog 4 months ago
Earnings expected next Thursday, a miss or a hit? Revenue a hit imo.

Form 4 filed
👍️0
jdheart101 jdheart101 4 months ago
200 July 2.5 calls @.88 . Be back soon !!!
👍️0
TIMGZ TIMGZ 4 months ago
INBS**** AS ALWAYS SUPER FAST COMPUTERS***WHALES***HEDGES FUNDS*** TRADERS MIGHT SURGE THE VOLUME AT A VERY HIGH FREQUENCY****


WITHIN MINUTES*****UPTREND

SEEMS SETTING UP NICELY FOR THAT
👍️0
BooDog BooDog 4 months ago
Still looking pretty good here. Did trim a few 2.38's thouigh. Not sure if we'll see a reset soon or not.

👍️0
glenn1919 glenn1919 5 months ago
LXRX..........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
jdheart101 jdheart101 5 months ago
Another 4000. @1.76
👍️0
Legend431 Legend431 5 months ago
Oops
👍️0
jdheart101 jdheart101 5 months ago
I’m in today 9500 @1.49 1/23/24
👍️0
BooDog BooDog 7 months ago
Ready to see this rock and roll. Get the Christmas rally going!

https://www.inpefahcp.com/


Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. Wikipedia
Stock price: LXRX (NASDAQ) $1.16 +0.01 (+1.32%)
Dec 6, 10:18?AM EST - Disclaimer
Headquarters: The Woodlands, TX
CEO: Lonnel Coats (Jul 7, 2014–)
Revenue: 324.1 million USD (2019)
Number of employees: 225 (2011)
Founded: 1995, The Woodlands, TX
Founder: Arthur T Sands
Subsidiaries: Lex-Gen Woodlands, L.P., Lexicon Pharmaceuticals (New Jersey), Inc
Product
https://www.lexpharma.com/

https://www.lexpharma.com/media-center/news
👍️0
BooDog BooDog 7 months ago
Insider buying... Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc

https://finance.yahoo.com/news/director-philippe-amouyals-strategic-200-060356510.html?guccounter=1&guce_referrer=aHR0cHM6Ly9maW52aXouY29tLw&guce_referrer_sig=AQAAAIoi6pMjBlhAAWCTqsgFDgJ_L3Mq27MaOD9VoCvqo193rq8IznDFhr2okgZCfdpTcOoOQpbq-htdQ0dRd_C7SPjLqq1-XLfxoxxNvrWLXCfYfWwGJkWm40NnRnChJ7IS-3NNjcnArKcxghtaIU9gZcRtqotAVRnZUPj9phWfJymM
👍️0
Monksdream Monksdream 7 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 8 months ago
$LXRX. Looking good. See this in a week or 2.

JMHO.
👍️0
glenn1919 glenn1919 8 months ago
LXRX................................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
TRADER99 TRADER99 8 months ago
Looks like we saw a bottom here with this spike in volume
👍️0
Monksdream Monksdream 9 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 9 months ago
Guess I wasn't watching the board here Monk. Have been watching the chart though and have been accumulating around 1.10' last week and added today.

Cheers
👍️0
Monksdream Monksdream 9 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
LXRX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
LXRX new 52 week low
👍️0
BooDog BooDog 10 months ago
LXRX 1.70's. Watching.
👍️0
BooDog BooDog 12 months ago
$LXRX https://finance.yahoo.com/news/lexicon-announces-planned-advancement-lx9211-004500120.html
Conference call this morning...

Conference Call and Webcast Information

Lexicon management will hold a live conference call and webcast Monday, June 26, 2023, at 8:00 am ET / 7:00 am CT. The dial-in number for the conference call is 888-317-6003 and the conference ID for all callers is 7186279. The live webcast and replay may be accessed by visiting Lexicon’s website at www.lexpharma.com/events. An archived version of the webcast will be available on the website for 14 days.
👍️0
BooDog BooDog 1 year ago
👍️0
BooDog BooDog 1 year ago
Quite the boost for institutionals.
https://www.sec.gov/Archives/edgar/data/1062822/000119312523160877/d449914dsc13da.htm
👍️0
BooDog BooDog 1 year ago
Agree. Too easy here. So predictable they'd be doing an offering though. Easy peasy this one is.
Taking nibbles in the 2.50's. Should have sold more on the highs yesterday.
👍️0
TIMGZ TIMGZ 1 year ago
LXRX MIGHT NOT BE LOOKING BACK AGAN, FDA APPROVED DRUG AND ALL BIG PHARMA EYEING. MY OPINION *******
ONE PAID $260M FOR BACKING OUT, NOW LOOK AT LXRX
👍️ 1
BooDog BooDog 1 year ago
2.75 support. See how it holds, or not. Interesting sell off.
👍️0
glenn1919 glenn1919 1 year ago
LXRX.........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
Hey there Glenn. This puppy has been excellent. Certainly one to keep an eye on.
👍️0
glenn1919 glenn1919 1 year ago
LXRX...........................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
If I se what I think I see, there's a reason shorts are leaving this puppy alone.

Added back in this morning but when something starts really moving you always say in hindsight that you should have bought more.
👍️0
glenn1919 glenn1919 1 year ago
LXRX.............................https://stockcharts.com/h-sc/ui?s=LXRX&p=W&b=5&g=0&id=p86431144783
👍️0
BooDog BooDog 1 year ago
High 2.96. Trip and rip potential. That's when the chart show either a tripple bottom or a tripple top and breaks through with some serious momentum.

See what this puppy does.


https://www.barchart.com/stocks/quotes/hils/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=LXRX&grid=1&height=210&studyheight=100
👍️0
BooDog BooDog 1 year ago
Passing 2.69.
👍️0
BooDog BooDog 1 year ago
Let's get the move on.
👍️0
BooDog BooDog 1 year ago
PUDUFA coming in a couple months. Looks like they're pretty confident.

GLTA
👍️0
makinezmoney makinezmoney 1 year ago
$LXRX: Time to load July $3 calls...... now $0.70

Why ????

1. Cash on Hand.............. $138.4Milly
2. Huge Insider buying of shares of $45Milly at $2.50sh
3. Piper Sandler with $10 Overweight assigned back in August last year
4. PDUFA coming in MAY
5. Largest OI is 1k on the July $3 calls


You know what that means right ???? They gotta a good feeling about that PDUFA
$LXRX now at $2.44......... last time it spiked ffrom $1.12 to $9.50 from Nov6,2020 to
Feb1, 2021 ..... 9x bagger !

Round 2 coming


GO $LXRX
👍️0
BooDog BooDog 2 years ago
Chart showing some strength. Closes over 2.20 and the bulls will be in the lead for next week imo.

LXRX daily
👍️0
BooDog BooDog 2 years ago
Lexicon Pharmaceuticals Announces Oral Presentations Relating To Its LX9211 Neuropathic Pain Program At The World Brain Disorders And Neuroscience Summit 2022

THE WOODLANDS, Texas, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the following two oral presentations relating to its investigational drug LX9211 will be delivered virtually during the World Brain Disorders and Neuroscience Summit 2022 Hybrid in Munich, Germany:

“Evaluation of LX9211 in the Treatment of Diabetic Peripheral Neuropathic Pain: Study Design and Topline Results from the RELIEF-DPN-1 Trial”, describes the positive results achieved in this proof-of-concept study and will be given on Saturday, October 29th at 3:25pm CEST/9:25am ET.


“Evaluation of LX9211, a Potent, Selective Inhibitor of AAK1, in Preclinical Models of Spasticity”, describes the effect of LX9211 in reducing spasticity in established animal models and will be given on Monday, October 31st at 3:35pm CET/8:35am ET.


https://finance.yahoo.com/news/lexicon-pharmaceuticals-announces-oral-presentations-125900260.html


Looks to be waking up.

LXRX chart
👍️0
BooDog BooDog 2 years ago
Bears are on the job. eom


LXRX chart

Message in reply to:
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

I'm looking for around $2. This looks like it's only starting to crack. Of course, news AND SOME VOLUME!!!! would certainly help.

No one answered me about the bear flag. So not sure if anyone did anything.
👍️0
BooDog BooDog 2 years ago
Bear flag forming. And right before the golden cross. Waiting to add.

Thinking 2.45 - 2.50 support may hold. Though depending on what really happens the $2 support looks stronger.

LXRX daily


All imo of course.
👍️0
BooDog BooDog 2 years ago
Nice to see the volume maintaining. Hope some were able to take advantage advantage of the dip.
👍️0

Your Recent History

Delayed Upgrade Clock